Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

First-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC

Zev Wainberg, MD, UCLA, discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC), which were presented at the virtual 2020 ESMO World Congress on Gastrointestinal Cancer.

 

Advertisement

Advertisement

Advertisement

Advertisement